Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 951-965

  Hrbacek, Jan ^a,b   Urban, Michael ^a,b   Hamsikova, Eva ^c   Tachezy, Ruth ^c   Heracek, Jiri ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Etiology; Infection; Prostate cancer; Serology; Sexually transmitted diseases

Indexed keywords

BK VIRUS; CARCINOGENESIS; CHLAMYDIA; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS; HUMAN; JC VIRUS; MYCOPLASMA; NEISSERIA; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROSTATE CANCER; REVIEW; TRICHOMONAS; TRICHOMONAS VAGINALIS; UREAPLASMA; UROGENITAL TRACT INFECTION; WART VIRUS; XENOTROPIC MULV RELATED VIRUS;

ETIOLOGY; INFECTION; PROSTATE CANCER; SEROLOGY; SEXUALLY TRANSMITTED DISEASES;

BACTERIAL INFECTIONS; HUMANS; MALE; MYCOSES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; VIRUS DISEASES;

EID: 84884670884     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.01.013     Document Type: Review

References (126)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
3. Kirby R.S., Patel M.I. Fast facts: Prostate cancer 2009, Health Press Limited, Oxford.
4. Giovannucci E., Liu Y., Platz E.A., et al. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007, 121:1571-1578.
5. Dennis L.K., Lynch C.F., Torner J.C. Epidemiologic association between prostatitis and prostate cancer. Urology 2002, 60:78-83.
6. Sutcliffe S., Giovannucci E., De Marzo A.M., et al. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:2160-2166.
7. Palapattu G.S., Sutcliffe S., Bastian P.J., et al. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2004, 26:1170-1181.
8. De Marzo A.M., Platz E.A., Sutcliffe S., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256-269.
9. Ravich A. Cancer of prostate; its relationship to circumcision. Acta Unio Int Contra Cancrum 1952, 8:351-353.
10. Strickler H.D., Goedert J.J. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001, 23:144-151.
11. Hayes R.B., Pottern L.M., Strickler H., et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000, 82:718-725.
12. Taylor M.L., Mainous A.G., Wells B.J. Prostate cancer and sexually transmitted diseases: A meta-analysis. Fam Med 2005, 37:506-512.
13. Huang W.Y., Hayes R., Pfeiffer R., et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:2374-2381.
14. Sutcliffe S., Platz E.A. Inflammation in the etiology of prostate cancer: An epidemiologic perspective. Urol Oncol 2007, 25:242-249.
15. Giuliano A.R., Tortolero-Luna G., Ferrer E., et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26(Suppl 10):K17-K28.
16. McNicol P.J., Dodd J.G. Detection of human papillomavirus DNA in Prostate Gland tissue by using the polymerase chain reaction amplification assay. J Clin Microbiol 1990, 28:409-412.
17. Lin Y., Mao Q., Zheng X., et al. Human papillomavirus 16 or 18 infection and prostate cancer risk: A meta-analysis. Ir J Med Sci 2011, 180:497-503.
18. Anwar K., Nakakuki K., Shiraishi T., et al. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992, 52:5991-5996.
19. Serth J., Panitz F., Paeslack U., et al. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999, 59:823-825.
20. Leiros G.J., Galliano S.R., Sember M.E., et al. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 2005, 5:15.
21. Sarkar F.H., Sakr W.A., Li Y.W., et al. Detection of human papillomavirus (HPV) DNA in human prostatic tissues by polymerase chain reaction (PCR). Prostate 1993, 22:171-180.
22. Strickler H.D., Burk R., Shah K., et al. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998, 82:1118-1125.
23. Zambrano A., Kalantari M., Simoneau A., et al. Detection of Human Polyomaviruses and Papillomaviruses in prostatic Tissue Reveals the Prostate as a Habitat for MultipleViral Infections. Prostate 2002, 53:263-276.
24. Martinez-Fierro M.L., Leach R.J., Gomez-Guerra L.S., et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 2010, 10:326.
25. Adami H.O., Kuper H., Andersson S.O., et al. Prostate cancer risk and Serologic evidence of human papilloma virus infection: A population-based Case-control study. Cancer Epidemiol Biomarkers Prev 2003, 12:872-875.
26. Dillner J., Knekt P., Boman J., et al. Sero-epidemiological association between human papillomavirus infection and risk of prostate cancer. Int J Cancer 1998, 75:564-567.
27. Hrbacek J., Urban M., Hamsikova E., et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: A case-control study. BMC Cancer 2011, 11:53.
28. Hrbacek J., Urban M., Eis V., et al. Genitourinary tract infections in patient history do not correlate with prostate cancer biological behaviour and prognosis. Ces Urol 2011, 15:172-180.
29. Sutcliffe S., Alderete J.F., Till C., et al. Trichomonosis and subsequent risk of prostate cancer in the prostate cancer prevention trial. Int J Cancer 2009, 124:2082-2087.
30. Staras S.A., Dollard S.C., Radford K.W., et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006, 43:1143-1151.
31. Samanta M., Harkins L., Klemm K., et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 2003, 170:998-1002.
32. Boldogh I., Baskar J.F., Mar E.C., et al. Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. J Natl Cancer Inst 1983, 70:819-826.
33. Eizuru Y., Hyman R.W., Nahhas W.A., et al. Herpesvirus RNA in human urogenital tumors. Proc Soc Exp Biol Med 1983, 174:296-301.
34. Bergh J., Marklund I., Gustavsson C., et al. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 2007, 96:137-139.
35. Leskinen M.J., Vainionp R., Syrjnen S., et al. Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer. Urology 2003, 61:397-401.
36. Sfanos K.S., Sauvageot J., Fedor H.L., et al. A molecular analysis of Prokaryotic and Viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 2008, 68:306-320.
37. Xu F., Schillinger J.A., Sternberg M.R., et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis 2002, 185:1019-1024.
38. Baker L.H., Mebust W.K., Chin T.D., et al. The relationship of herpesvirus to carcinoma of the prostate. J Urol 1981, 125:370-374.
39. Dennis L.K., Coughlin J.A., McKinnon B.C., et al. Sexually transmitted infections and prostate cancer among men in the U.S. Military. Cancer Epidemiol Biomarkers Prev 2009, 18:2665-2671.
40. Korodi Z., Wang X., Tedeschi R., et al. No serological evidence of association between prostate cancer and infection with herpes simplex virus type 2 or human herpesvirus type 8: A nested case-control study. J Infect Dis 2005, 191:2008-2011.
41. Monini P., de Lellis L., Fabris M., et al. Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med 1996, 334:1168-1172.
42. Rubin M.A., Parry J.P., Singh B. Kaposi's sarcoma associated herpesvirus deoxyribonucleic acid sequences: Lack of detection in prostatic tissue of human immunodeficiency virus-negative immunocompetent adults. J Urol 1998, 159:146-148.
43. Diamond C., Brodie S.J., Krieger J.N., et al. Human herpesvirus 8 in the prostate glands of men with Kaposi's sarcoma. J Virol 1998, 72:6223-6227.
44. Corbellino M., Bestetti G., Galli M., et al. Absence of HHV-8 in prostate and semen. N Engl J Med 1996, 335:1237.
45. Blackbourn D.J., Levy J.A. Human herpesvirus 8 in semen and prostate. AIDS 1997, 11:249-250.
46. Hoffman L.J., Bunker C.H., Pellett P.E., et al. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J Infect Dis 2004, 189:15-20.
47. Sutcliffe S., Giovannucci E., Gaydos C.A., et al. Serum antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2007, 16:1573-1580.
48. Grinstein S., Preciado M.V., Gattuso P., et al. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res 2002, 62:4876-4878.
49. González A.B., Urban M.I., Sitas F., et al. Antibodies against six human herpesviruses in relation to seven cancers in black South Africans: A case control study. Infect Agents Cancer 2006, 1:2.
50. Tognon M., Corallini A., Martini F., et al. Oncogenic transformation by BK virus and association with human tumors. Oncogene 2003, 22:5192-5200.
51. Monini P., Rotola A., Di Luca D., et al. DNA rearrangements impairing BK virus productive infection in urinary tract tumors. Virology 1995, 214:273-279.
52. Das D., Shah R.B., Imperiale M.J. Detection and expression of human BK virus sequences in neoplastic prostate tissues. Oncogene 2004, 23:7031-7046.
53. Das D., Wojno K., Imperiale M.J. BK virus as a cofactor in the etiology of prostate cancer in its early stages. J Virol 2008, 82:2705-2714.
54. Russo G., Anzivino E., Fioriti D., et al. p53 gene mutational rate, Gleason score, and BK virus infection in prostate adenocarcinoma: Is there a correlation?. J Med Virol 2008, 80:2100-2107.
55. Newton R., Ribeiro T., Casabonne D., et al. Antibody levels against BK virus and prostate, kidney and bladder cancers in the EPIC-Oxford cohort. Br J Cancer 2005, 93:1305-1306.
56. Wagenlehner F.M.E., Weidner W., Naber K.G. Chlamydial infections in urology. World J Urol 2006, 24:4-12.
57. Antilla T., Tenkanen L., Lumme S., et al. Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:385-389.
58. Corradi G., Bucsek M., Pánovics J., et al. Detection of Chlamydia trachomatis in the prostate by in-situ hybridization and by transmission electron microscopy. Int J Androl 1996, 19:109-112.
59. Johnston V.J., Mabey D.C. Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 2008, 21:56-64.
60. Sutcliffe S., Giovannucci E., Alderete J.F., et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:939-945.
61. Ketcham C.M., Anai S., Reutzel R., et al. p37 induces tumor invasiveness. Mol Cancer Ther 2005, 4:1031-1038.
62. Namiki K., Goodison S., Porvasnik S., et al. Persistent exposure to mycoplasma induces malignant transformation of human prostate cells. PLoS ONE 2009, 4:e6872.
63. Urbanek C., Goodison S., Chang M., et al. Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer 2011, 11:233.
64. Barykova Y.A., Logunov D.Y., Shmarov M.M., et al. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget 2011, 2:289-297.
65. Krieger J.N., Riley D.E., Vesella R.L., et al. Bacterial dna sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. J Urol 2000, 164:1221-1228.
66. Alexeyev O., Bergh J., Marklund I., et al. Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control 2006, 17:1127-1133.
67. Alexeyev O.A., Marklund I., Shannon B., et al. Direct visualization of Propionibacterium acnes in prostate tissue by multicolor fluorescent in situ hybridization assay. J Clin Microbiol 2007, 45:3721-3728.
68. Fassi Fehri L., Mak T.N., Laube B., et al. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int J Med Microbiol 2011, 301:69-78.
69. Severi G., Shannon B.A., Hoang H.N., et al. Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: Results from an Australian population-based case-control study. Br J Cancer 2010, 103:411-415.
70. Urisman A., Molinaro R.J., Fischer N., et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNaseL variant. PLoS Pathog 2006, 2:e25.
71. Bisbal C., Silverman R.H. Diverse functions of RNase L and implications in pathology. Biochimie 2007, 89:789-798.
72. Chakrabarti A., Jha B.K., Silverman R.H. New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res 2011, 31:49-57.
73. Hué S., Gray E.R., Gall A., et al. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010, 7:111.
74. Cohen J., Enserink M. Virology. False positive. Science 2011, 333:1694-1701.
75. Dalton-Griffin L., Kellam P. Infectious causes of cancer and their detection. J Biol 2009, 8:67.
76. McNicol P.J., Dodd J.G. High prevalence of human papillomavirus in prostate tissues. J Urol 1991, 145:850-853.
77. Masood S., Rhatigan R.M., Powell S., et al. Human papillomavirus in prostatic cancer: No evidence found by in situ hybridization. South Med J 1991, 84:235-236.
78. Effert P.J., Frye R.A., Neubauer A., et al. Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: Analysis of archival human prostate cancer specimens by differential polymerase chain reaction. J Urol 1992, 147:192-196.
79. Serfling U., Ciancio G., Zhu W.Y., et al. Human papillomavirus and herpes virus DNA are not detected in benign and malignant prostastic tissue using the polymerase chain reaction. J Urol 1992, 148:192-194.
80. Rotola A., Monini P., DiLuca D., et al. Presence and physical state of HPV DNA in prostate and urinary tract tissues. Int J Cancer 1992, 52:359-365.
81. Ibrahim G.K., Gravitt P.E., Dittrich K.L., et al. Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization. J Urol 1992, 148:1822-1826.
82. Dodd J.G., Paraskevas M., McNicol P.J. Detection of human papillomavirus 16 transcription in human prostate tissue. J Urol 1993, 149:400-402.
83. Sarkar F.H., Sakr W.A., Li Y.W., et al. Detection of human papillomavirus (HPV) DNA in human prostatic tissues by polymerase chain reaction (PCR). Prostate 1993, 22:171-180.
84. Tu H., Jacobs S.C., Mergner W.J., et al. Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer. Urology 1994, 44:726-731.
85. Moyret-Lalle C., Marçais C., Jacquemier J., et al. p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995, 64:124-129.
86. Suzuki H., Komiya A., Aida S., et al. Detection of human papillomavirus DNA and p53 Gene mutations in human prostate cancer. Prostate 1996, 28:318-324.
87. Wideroff L., Schottenfeld D., Carey T.E., et al. Human papillomavirus DNA in malignant and hyperplastic prostate tissue of Black and White males. Prostate 1996, 28:117-123.
88. Anderson M., Handley J., Hopwood L., et al. Analysis of prostate tissue DNA for the presence of human papillomavirus by polymerase chain reaction, cloning, and automated sequencing. J Med Virol 1997, 52:8-13.
89. Noda T., Sasagawa T., Dong Y., et al. Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res 1998, 26:165-169.
90. Strickler H.D., Burk R., Shah K., et al. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998, 82:1118-1125.
91. Saad F., Gu K., Jean-Baptiste J., et al. Absence of human papillomavirus sequences in early stage prostate cancer. Can J Urol 1999, 6:834-838.
92. Carozzi F., Lombardi F.C., Zendron P., et al. Association of human papillomavirus with prostate cancer: Analysis of a consecutive series of prostate biopsies. Int J Biol Markers 2004, 19:257-261.
93. Balis V., Sourvinos G., Soulitzis N., et al. Prevalence of BK virus and human papillomavirus in human prostate cancer. Int J Biol Markers 2007, 22:245-251.
94. Gazzaz F.S., Hisham A.M. Lack of detection of human papillomavirus infection by hybridization test in prostatic biopsies. Saudi. J Med 2009, 30:633-637.
95. Silvestre R.V., Leal M.F., Demachki S., et al. Low frequency of human papillomavirus detection in prostate tissue from individuals from Northern Brazil. Mem Inst Oswaldo Cruz 2009, 104:665-667.
96. Aghakhani A., Hamkar R., Parvin M., et al. The role of human papillomavirus infection in prostate carcinoma. Scand J Infect Dis 2011, 43:64-69.
97. Baker L.H., Mebust W.K., Chin T.D., et al. The relationship of herpesvirus to carcinoma of the prostate. J Urol 1981, 125:370-374.
98. Haid M., Sharon N. Immunofluorescent evidence of prior herpes simplex virus type-2 infection in prostate carcinoma. Urology 1984, 24:623-625.
99. Tasaka T., Said J.W., Morosetti R., et al. Is Kaposi's sarcoma-associated herpesvirus ubiquitous in urogenital and prostate tissues?. Blood 1997, 89:1686-1689.
100. Lebbé C., Pellet C., Tatoud R., et al. Absence of human herpesvirus 8 sequence in prostate specimens. AIDS 1997, 11:70.
101. Lau S.K., Lacey S.F., Chen Y.Y., et al. Low frequency of BK virus in prostatic adenocarcinomas. APMIS 2007, 115:743-749. 2007.
102. Monini P., Rotola A., de Lellis L., et al. Latent BK virus infection and Kaposi's sarcoma pathogenesis. Int J Cancer 1996, 66:717-722.
103. Akgül B., Pfister D., Knüchel R., et al. No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of German patients. Med Microbiol Immunol 2011; Sep 6, [Epub ahead of print].
104. Hisada M., Rabkin C.S., Strickler H.D., et al. Human papillomavirus antibody and risk of prostate cancer. JAMA 2000, 3:340-341.
105. Rosenblatt K.A., Carter J.J., Iwasaki L.M., et al. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:763-768.
106. Korodi Z., Dillner J., Jellum E., et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: A Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005, 14:2952-2955.
107. Sitas F., Urban M., Stein L., et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agents Cancer 2007, 2:6.
108. Sutcliffe S., Giovannucci E., Gaydos C.A., et al. Serum antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2007, 16:1573-1580.
109. Sutcliffe S., Viscidi R.P., Till C., et al. Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2010, 19:614-618.
110. Mandel J.S., Schuman L.M. Sexual factors and prostatic cancer: Results from a case-control study. J Gerontol 1987, 42:259-264.
111. Jenkins F.J., Hayes R.B., Jackson A., et al. Human herpesvirus 8 seroprevalence among prostate cancer case patients and control subjects. J Infect Dis 2007, 196:208-211.
112. McDonald A.C., Jenkins F.J., Bunker C.H., et al. A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. Infect Agents Cancer 2011, 6:25.
113. Stark J.R., Judson G., Alderete J.F., et al. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' health study. J Natl Cancer Inst 2009, 101:1406-1411.
114. Fischer N., Hellwinkel O., Schulz C., et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 2008, 43:277-283.
115. Hohn O., Krause H., Barbarotto P., et al. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology 2009, 6:92.
116. Schlaberg R., Choe D.J., Brown K.R., et al. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A 2009, 106:16351-16356.
117. Aloia A.L., Sfanos K.S., Isaacs W.B., et al. XMRV: A new virus in prostate cancer?. Cancer Res 2010, 70:10028-10033.
118. Arnold R.S., Makarova N.V., Osunkoya A.O., et al. XMRV infection in patients with prostate cancer: Novel serologic assay and correlation with PCR and FISH. Urology 2010, 75:755-761.
119. Danielson B.P., Ayala G.E., Kimata J.T. Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis 2010, 15:1470-1477.
120. Arredondo M., Hackett J., de Bethencourt F.R., et al. Prevalence of XMRV infection in different risk populations in Spain. AIDS Res Hum Retrovir 2011; Feb 21, [Epub ahead of print].
121. Furuta R.A., Miyazawa T., Sugiyama T., et al. No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology 2011, 17:8. 20.
122. Sakuma T., Hué S., Squillace K.A., et al. No evidence of XMRV in prostate cancer cohorts in the midwestern United States. Retrovirology 2011, 8:23.
123. Sabunciyan S., Mandelberg N., Rabkin C.S., et al. No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls. Mol Cell Probes 2011, 25:134-136.
124. Stieler K., Schindler S., Schlomm T., et al. No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS ONE 2011, 6:e25592.
125. Switzer W.M., Jia H., Zheng H., et al. No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS ONE 2011, 6:e19065.
126. Verhaegh G.W., de Jong A.S., Smit F.P., et al. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate 2011, 71:415-420.